Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...
The cohort used for the approved indication was conducted at 40 sites in 7 countries in North America and Europe. [ 37 ] In 2022, an early clinical study of dostarlimab reported a 100% remission rate in 14 patients with rectal cancer who had mismatch repair deficiency, a type of genetic mutation that only affects 5-10% of cases.
The Keytruda combination was approved for patients with cervical cancer who had not previously received surgery, radiation, or systemic therapy, FDA said. This makes Keytruda plus ...
The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients. The U.S. drugmaker is ...
Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or ...
Common side effects of valproate include nausea, vomiting, somnolence, and dry mouth. [7] Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended. [7] Other serious risks include pancreatitis and an increased suicide risk. [7]
The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.